MSB 3.21% $1.13 mesoblast limited

WHO Solidarity Trial Results, page-6

  1. 92 Posts.
    lightbulb Created with Sketch. 93
    I think SI will want to continue to complete the full COVID trial to get as much data as possible, so that if the trial is successful the FDA have as little grounds as possible to delay with a CRL for more data required. Particularly after the CRL for GvHD.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.